Who are we?
Anagenesis Biotechnologies is a preclinical‐stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs.
Anagenesis Biotechnologies secured two private investments from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area and from Cap Innov’Est. Anagenesis Biotechnologies aim is to become the world leader in muscle-related diseases.